In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Seattle Genetics public offering nets $659mm to fund Cascadian purchase

02 Feb 2018

Executive Summary

Seattle Genetics Inc. (targeted antibody-based cancer therapies) netted $659mm through a public offering of 13.27mm common shares (including the overallotment) at $52. Proceeds will fund the firm's acquisition of Cascadian Therapeutics; on the same day it announced the FOPO, Seattle Genetics offered $10 per share or approximately $614mm to purchase the oncology drug development company.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By